Active

Nova Chara Ltd

#814351 Private limited by shares

Nova Chara Ltd is a private company limited by shares registered in Ireland on 24 April 2026 (company number 814351), based in Dublin 7, Co. Dublin. Current status on the CRO register: Active.

Company Details

Registered Name NOVA CHARA LIMITED
Company Number 814351
Company Type Private limited by shares
Type Code 1119
Status Normal

Important Dates

Registration Date 24 April 2026
Last Annual Return N/A
Last Accounts Filed N/A

Industry Classification (NACE)

NACE Code: 62.09

Registered Address

THE BLACK CHURCH

ST. MARY'S PLACE,Dublin 7

D07P4AX

Contact Details

Phone Number Unknown
Email Address Unknown

Company Website

Company Description

Nova Chara Limited is an Irish-registered company dedicated to redefining pharmaceutical manufacturing and data validation. The business operates through two specialized divisions, Isotopic Integrity and Hyperbolic Tapering Core, to bridge the gap between non-deterministic data models and physical operational limits within the life sciences ecosystem. Its mission focuses on guaranteeing absolute integrity, precision, and compliance in the development of next-generation health-tech therapies.

The Isotopic Integrity division deploys advanced, constraint-based validation architectures designed to eliminate systemic variance in high-fidelity data structures. By establishing deterministic boundaries within analytical pipelines, the platform isolates computational anomalies to ensure absolute operational verification. This addresses the high regulatory scrutiny on computational errors and algorithmic anomalies currently facing the life sciences sector.

Hyperbolic Tapering Core engineers next-generation precision systems and specialized structural frameworks to optimize automated asset deployment. This hardware-software integration introduces novel, geometry-optimized mechanics that de-risk scalability and transform throughput efficiency in complex manufacturing environments. Nova Chara provides the foundational software validation architectures and high-precision physical deployment frameworks required to support the safe scaling of next-generation therapies from synthesis to delivery.